Shares of DBV Technologies SA – (NASDAQ:DBVT) have received an average recommendation of “Hold” from the thirteen brokerages that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $48.83.

Several research analysts recently commented on the company. BidaskClub cut DBV Technologies from a “sell” rating to a “strong sell” rating in a research report on Wednesday. Societe Generale cut DBV Technologies from a “buy” rating to a “sell” rating in a research report on Tuesday, October 24th. Zacks Investment Research cut DBV Technologies from a “buy” rating to a “hold” rating in a research report on Friday, September 29th. Jefferies Group reaffirmed a “buy” rating on shares of DBV Technologies in a research report on Thursday, August 31st. Finally, JMP Securities assumed coverage on DBV Technologies in a research report on Friday, November 17th. They issued an “outperform” rating for the company.

Large investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC acquired a new stake in shares of DBV Technologies in the third quarter valued at $132,000. Quantbot Technologies LP acquired a new stake in shares of DBV Technologies in the third quarter valued at $146,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of DBV Technologies in the second quarter valued at $222,000. Commonwealth Equity Services Inc acquired a new stake in shares of DBV Technologies in the third quarter valued at $233,000. Finally, Airain ltd acquired a new stake in shares of DBV Technologies in the second quarter valued at $333,000. Institutional investors own 46.94% of the company’s stock.

DBV Technologies (NASDAQ DBVT) opened at $21.23 on Friday. DBV Technologies has a 12-month low of $20.58 and a 12-month high of $50.57.

ILLEGAL ACTIVITY NOTICE: “DBV Technologies SA – (DBVT) Receives Consensus Rating of “Hold” from Brokerages” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/12/08/dbv-technologies-sa-dbvt-receives-consensus-rating-of-hold-from-brokerages.html.

DBV Technologies Company Profile

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies SA - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies SA - and related companies with MarketBeat.com's FREE daily email newsletter.